CareLit · DOI-Nachweis · Pneumologie
Safety, Efficacy, and Tolerability of Tezacaftor/Ivacaftor in Cystic Fibrosis Patients Who Previously Discontinued Lumacaftor/Ivacaftor Due To Respiratory Adverse Events: A Randomized, Double-Blind, Placebo-Controlled Phase 3b Study
DOI 10.1055/s-0039-1678160
Bibliografische Angaben
Nachweis in CareLit
Autor:innenC Schwarz, S Sutharsan, R Epaud, R Klingsberg, R Fischer, SM Rowe, P Audhya, L Wang, X You, T Ferro
ZeitschriftPneumologie
AusgabeS 01 S 01/2019
Jahrgang / SeitenJg. 73
Kernaussage aus der Literatur
Abstract-Vorschau
Safety, Efficacy, and Tolerability of Tezacaftor/Ivacaftor in Cystic Fibrosis Patients Who Previously Discontinued Lumacaftor/Ivacaftor Due To Respiratory Adverse Events: A Randomized, Double-Blind, Placebo-Controlled Phase 3b Study
Zitieren
Zitierempfehlung
C Schwarz, S Sutharsan, R Epaud, R Klingsberg, R Fischer, SM Rowe, P Audhya, L Wang, X You, T Ferro (2019) Safety, Efficacy, and Tolerability of Tezacaftor/Ivacaftor in Cystic Fibrosis Patients Who Previously Discontinued Lumacaftor/Ivacaftor Due To Respiratory Adverse Events: A Randomized, Double-Blind, Placebo-Controlled Phase 3b Study. Pneumologie, 73 (S 01 S 01). https://doi.org/10.1055/s-0039-1678160
Mit CareLit weiterarbeiten